These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 1422236)

  • 1. Immunosuppressive treatment of Graves' ophthalmopathy.
    Wiersinga WM
    Thyroid; 1992; 2(3):229-33. PubMed ID: 1422236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
    Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
    Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.
    Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Lepri A; Pinchera A
    J Endocrinol Invest; 1991 Nov; 14(10):853-60. PubMed ID: 1802923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma exchange therapy for severe Graves' ophthalmopathy.
    Glinoer D; Schrooyen M
    Horm Res; 1987; 26(1-4):184-9. PubMed ID: 3596467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Corticosteroids and radiotherapy in the treatment of Graves' ophthalmopathy].
    Nasr E; Khater S; Nehme-Nasr D; Azoury F; Jambart S
    J Med Liban; 2010; 58(2):86-90. PubMed ID: 20549894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy.
    Matejka G; Vergès B; Vaillant G; Petit JM; Brun-Pacaud A; Rudoni S; Brun JM
    Horm Metab Res; 1998 Feb; 30(2):93-8. PubMed ID: 9543692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial.
    Wakelkamp IM; Baldeschi L; Saeed P; Mourits MP; Prummel MF; Wiersinga WM
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):323-8. PubMed ID: 16117821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].
    Brauer VF; Scholz GH
    Med Klin (Munich); 2004 Feb; 99(2):71-6. PubMed ID: 14963657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graves' ophthalmopathy--a clinical review.
    Carter JN
    Aust N Z J Ophthalmol; 1990 Aug; 18(3):239-42. PubMed ID: 2261168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophthalmopathy.
    Utech CI; Khatibnia U; Winter PF; Wulle KG
    Thyroid; 1995 Jun; 5(3):185-93. PubMed ID: 7580266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating severe Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Pinchera A
    Baillieres Clin Endocrinol Metab; 1997 Oct; 11(3):521-36. PubMed ID: 9532337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.
    Mourits MP; Prummel MF; Wiersinga WM; Koornneef L
    Clin Endocrinol (Oxf); 1997 Jul; 47(1):9-14. PubMed ID: 9302365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM
    Thyroid; 1995 Jun; 5(3):231-4. PubMed ID: 7580273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
    Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
    Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Graves' ophthalmopathy.
    Wiersinga WM
    Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orbital radiotherapy for Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Tanda ML; Rocchi R; Mazzi B; Barbesino G; Pinchera A
    Thyroid; 2002 Mar; 12(3):245-50. PubMed ID: 11952048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy].
    Yang H; Wu Z; Huang X; Xie C; Yang P
    Yan Ke Xue Bao; 1999 Jun; 15(2):78-80. PubMed ID: 12579704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orbital cobalt radiotherapy and systemic or retrobulbar corticosteroids for Graves' ophthalmopathy.
    Pinchera A; Marcocci C; Bartalena L; Panicucci M; Marconcini C; Lepri A; Cavallacci G; Cartei F; Laddaga M
    Horm Res; 1987; 26(1-4):177-83. PubMed ID: 3596466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.